Dupixent is available as a solution inside single-dose prefilled pens and syringes, given as a subcutaneous injection. Dupixent is a biologic and belongs to a drug class called interleukin-4 (IL-4 ...

Despite lackluster sales of Eylea’s high-dose formulation and Sanofi-partnered Dupixent, Regeneron beat Q4 forecasts overall ...

These drugs inhibit interleukin (IL)-5, while Dupixent inhibits IL-4 and IL-13, but can be considered a rival because it is also an injection. Patients may opt to take the others because of their ...

The company’s Eylea product line, particularly the Eylea HD, has promising developments with a pre-filled syringe application ... the successful launch of Dupixent for chronic obstructive ...

CEO Leonard Schleifer highlighted 10% revenue growth in Q4 2024, attributed to strong performance from Dupixent ... with the launch of a prefilled syringe in mid-2025 and label expansions for ...

Sanofi is already a major player in the ASD market with its big-selling IL-4 and IL-13 inhibitor Dupixent (dupilumab), and the company has previously highlighted amlitelimab as one of a dozen ...

One primary reason is the strong performance and potential of Dupixent, which is expected to partially counterbalance the uncertainties surrounding Eylea. The expected growth in Dupixent’s ...

The use of combination vaccines could simplify immunisation programmes, offering quicker administration, fewer injections, reduced errors and decreased syringe ... Regeneron's Dupixent for ...

Among other topics, Hudson discussed the success of Dupixent (dupilumab), highlighting that it has reached over $13bn in global sales, which affirms its commercial advantage and sets a milestone ...